Display options
Cite
Chen YC, Moseson DE, Richard CA, et al. Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam. J Control Release. 2022;342:189-200doi: 10.1016/j.jconrel.2021.12.038.
Chen, Y. C., Moseson, D. E., Richard, C. A., Swinney, M. R., Horava, S. D., Oucherif, K. A., Cox, A. L., Hawkins, E. D., Li, Y., DeNeve, D. F., Lomeo, J., Zhu, A., Lyle, L. T., Munson, E. J., Taylor, L. S., Park, K., & Yeo, Y. (2022). Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam. Journal of controlled release : official journal of the Controlled Release Society, 342189-200. https://doi.org/10.1016/j.jconrel.2021.12.038
Chen, Yun-Chu, et al. "Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam." Journal of controlled release : official journal of the Controlled Release Society vol. 342 (2022): 189-200. doi: https://doi.org/10.1016/j.jconrel.2021.12.038
Chen YC, Moseson DE, Richard CA, Swinney MR, Horava SD, Oucherif KA, Cox AL, Hawkins ED, Li Y, DeNeve DF, Lomeo J, Zhu A, Lyle LT, Munson EJ, Taylor LS, Park K, Yeo Y. Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam. J Control Release. 2022 Jan 03;342:189-200. doi: 10.1016/j.jconrel.2021.12.038. Epub 2022 Jan 03. PMID: 34990702.
Copy Download .nbib Format: NLM
Share it on

J Control Release. 2022 Jan 03;342:189-200. doi: 10.1016/j.jconrel.2021.12.038. Epub 2022 Jan 03.

Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam.

Journal of controlled release : official journal of the Controlled Release Society

Yun-Chu Chen, Dana E Moseson, Coralie A Richard, Monica R Swinney, Sarena D Horava, Kaoutar Abbou Oucherif, Amy L Cox, Eric D Hawkins, Yongzhe Li, Daniel F DeNeve, Joshua Lomeo, Aiden Zhu, L Tiffany Lyle, Eric J Munson, Lynne S Taylor, Kinam Park, Yoon Yeo

Affiliations

  1. Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.
  2. Eli Lilly and Company, 893 Delaware Street, Indianapolis, IN 46225, USA.
  3. Eli Lilly and Company, 450 Kendall Street, Cambridge, MA 02142, USA.
  4. Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA; Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, PR China.
  5. DigiM Solution LLC, 67 South Bedford Street, West Burlington, MA 01803, USA.
  6. Department of Comparative Pathobiology, Purdue University, 625 Harrison Street, West Lafayette, IN 47907, USA.
  7. Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA.
  8. Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA. Electronic address: [email protected].

PMID: 34990702 DOI: 10.1016/j.jconrel.2021.12.038

Abstract

For effective resolution of regional subacute inflammation and prevention of biofouling formation, we have developed a polymeric implant that can release meloxicam, a selective cyclooxygenase (COX)-2 inhibitor, in a sustained manner. Meloxicam-loaded polymer matrices were produced by hot-melt extrusion, with commercially available biocompatible polymers, poly(ε-caprolactone) (PCL), poly(lactide-co-glycolide) (PLGA), and poly(ethylene vinyl acetate) (EVA). PLGA and EVA had a limited control over the drug release rate partly due to the acidic microenvironment and hydrophobicity, respectively. PCL allowed for sustained release of meloxicam over two weeks and was used as a carrier of meloxicam. Solid-state and image analyses indicated that the PCL matrices encapsulated meloxicam in crystalline clusters, which dissolved in aqueous medium and generated pores for subsequent drug release. The subcutaneously implanted meloxicam-loaded PCL matrices in rats showed pharmacokinetic profiles consistent with their in vitro release kinetics, where higher drug loading led to faster drug release. This study finds that the choice of polymer platform is crucial to continuous release of meloxicam and the drug release rate can be controlled by the amount of drug loaded in the polymer matrices.

Copyright © 2022 Elsevier B.V. All rights reserved.

Keywords: Biocompatible polymer; Hot-melt extrusion; Implant; Meloxicam; Sustained drug delivery

Publication Types